Xenon Pharmaceuticals Inc. (XENE) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Burnaby, BC, 캐나다. 현재 CEO는 Ian C. Mortimer.
XENE 을(를) 보유 IPO 날짜 2014-11-05, 316 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $4.69B.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's pipeline includes XEN496 and XEN1101, both Kv7 potassium channel openers in clinical development for epilepsy and related conditions, as well as NBI-921352, a sodium channel inhibitor in Phase II trials for developmental and epileptic encephalopathy. Additionally, Xenon is advancing XEN007, a central nervous system calcium channel modulator, and has partnered with Neurocrine Biosciences for epilepsy treatments and Flexion Therapeutics for pain management applications. Founded in 1996, the company is committed to addressing significant unmet medical needs in neurological disorders through its targeted drug development approach.
